Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
549
NCT03340883
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Nov 15, 2017
Completion: Jul 9, 2019
NCT04573478
Atrasentan in Patients With IgA Nephropathy
Phase: Phase 3
Start: Dec 11, 2020
Completion: Dec 18, 2026
NCT05367661
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers
Phase: Phase 1
Start: Apr 8, 2022
Completion: Apr 19, 2023
NCT05508204
Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects
Start: Jul 19, 2022
Completion: Dec 16, 2022